Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytomegalovirus-specific cytotoxic T lymphocytes (CMV-CTLs) are a form of adoptive cell therapy used for preventing and treating cytomegalovirus (CMV) infections in immunocompromised patients, particularly following hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. These are T cells that specifically target and eliminate cells infected with CMV. The therapy involves isolating, selecting, and sometimes expanding CMV-specific T cells from a donor (either the original transplant donor or a third-party donor) and infusing them into the recipient to provide immediate antiviral immunity. CMV-CTLs can penetrate the blood-brain barrier and blood vitreous barrier, making them effective against CMV infections in the central nervous system and retina.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cytomegalovirus-specific cytotoxic T lymphocytes.